Salvage therapy of small volume prostate cancer nodal failures: A review of the literature

Critical Reviews in Oncology/Hematology

Volumn 90, Issue 1, 2014, Pages 24-35

  De Bari, Berardino ^a   Alongi, Filippo ^b   Buglione, Michela ^a   Campostrini, Franco ^c   Briganti, Alberto ^d   Berardi, Genoveffa ^e   Petralia, Giuseppe ^f   Bellomi, Massimo ^f   Chiti, Arturo ^b   Fodor, Andrei ^e   Suardi, Nazareno ^d   Cozzarini, Cesare ^e   Nadia, Di Muzio ^e   Scorsetti, Marta ^b   Orecchia, Roberto ^g   Montorsi, Francesco ^d   Bertoni, Filippo ^h   Magrini, Stefano Maria ^a   Jereczek Fossa, Barbara Alicja ^g  

^a UNIVERSITY OF BRESCIA   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c Legnago Hospital   (Italy)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h Modena Hospital   (Italy)

Author keywords

ADT prostate; Nodal relapse; Oligo recurrent disease; PET prostate; Prostate cancer; Radiotherapy; Salvage lymph node dissection; SBRT; Surgery

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGO RECURRRENCE; OLIGOMETASTASIS; PATIENT SELECTION; PROSTATE CANCER; REVIEW; RISK BENEFIT ANALYSIS; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; STEREOTACTIC BODY RADIATION THERAPY; TUMOR VOLUME;

ADT PROSTATE; NODAL RELAPSE; OLIGO-RECURRENT DISEASE; PET PROSTATE; PROSTATE CANCER; RADIOTHERAPY; SALVAGE LYMPH NODE DISSECTION; SBRT; SURGERY;

HUMANS; LYMPH NODES; MALE; MULTIMODAL IMAGING; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATIC NEOPLASMS; SALVAGE THERAPY;

EID: 84895423213     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.11.003     Document Type: Review

References (91)

1. Wiechselbaum R.R., Hellman S. Oligometastases revisited. Nat Rev Clin Oncol 2011, 8:378-382.
2. Chua T.C., Liauw W., Chu F., Morris D.L. Viewing metastatic colorectal cancer as curable chronic disease. Am J Clin Oncol 2012, 35:77-80.
3. Gronau E., Goppelt M., Harzmann R., et al. Prostate cancer relapse after therapy with curative intention: a diagnostic and therapeutic dilemma. Onkologie 2005, 28:361-366.
4. Mottet N., Bellmunt J., Bolla M., et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011, 59((4) April):572-583.
5. Salonen A.J., Taari K., Ala-Opas M., et al. Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised Finn Prostate Study VII: quality of life and adverse effects. Eur Urol 2012, [Epub ahead of print].
6. Niibe Y., Chang J.Y. Novel insights of oligometastases and oligo-recurrence and review of the literature. Pulm Med 2012, 2012:261096. 10.1155/2012/261096.
7. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002, 2(8):563-572.
8. Fidler I.J. The pathogenesis of cancer metastasis: the seed and soil hypothesis revisited. Nat Rev Cancer 2003, 3(6):453-458.
9. Hovels A.M., Heesakkers R.A.M., Adang E.M., et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008, 63:387-395.
10. Giannarini G., Petralia G., Thoeny H.C., et al. Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer, including pelvic lymph node staging: a critical analysis of the literature. Eur Urol 2012, 61:326-340.
11. Mattei A., Danuser H. Contemporary imaging analyses of pelvic lymph nodes in the prostate cancer patients. Curr Opin Urol 2011, 21:211-218.
12. Heesakkers R.A., Hovels A.M., Jager G.J., et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 2008, 9:850-856.
13. Golimbu M., Morales P., Al-Askari S., et al. CAT scanning in staging of prostatic cancer. Urology 1981, 18:302-308.
14. Flanigan R.C., Mohler J.L., King C.T., et al. Preoperative lymph node evaluation in prostatic cancer patients who are surgical candidates: the role of lymphangiography and computerized tomography scanning with directed fine needle aspiration. J Urol 1985, 134:84-87.
15. Van Poppel H., Ameye F., Oyen R., et al. Accuracy of combined computerized tomography and fine needle aspiration cytology in lymph node staging of localized prostatic carcinoma. J Urol 1994, 151:1310-1314.
16. Rorvik J., Halvorsen O.J., Albrektsen G., et al. Lymphangiography combined with biopsy and computer tomography to detect lymph node metastases in localized prostate cancer. Scand J Urol Nephrol 1998, 32:116-119.
17. Lecouvet F.E., El Mouedden J., Collette L., et al. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?. Eur Urol 2012, 62:68-75.
18. Bezzi M., Kressel H.Y., Allen K.S., et al. Prostatic carcinoma: staging with MR imaging at 1,5T. Radiology 1988, 169:339-346.
19. Rifkin M.D., Zerhouni E.A., Gatsonis C.A., et al. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer: results of a multi-institutional cooperative trial. N Engl J Med 1990, 323:621-626.
20. Jager G.J., Barentz J.O., Oosterhof G.O., et al. Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional T1-weighted magnetization-prepared-rapid gradient-echo sequence. Am J Roentgenol 1996, 167:1503-1507.
21. Perrotti M., Kaufman R.P., Jennings T.A., et al. Endo-rectal coil magnetic resonance imaging in clinically localized prostate cancer: is it accurate?. J Urol 1996, 156((1) July):106-109.
22. Harisinghani M.G., Barentsz J., Hahn P.F., et al. Non-invasive detection of clinically occult lymph node metastases in prostate cancer. N Engl J Med 2003, 348:2491-2499.
23. Wang L., Hricak H., Kattan M.W., et al. Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer. Am J Roentgenol 2006, 186:743-748.
24. Eiber M., Beer A.J., Holzapfel K., et al. Preliminary results for characterization of pelvic lymh nodes in patients with prostate cancer by diffusion-weighted MR-imaging. Invest Radiol 2010, 45:15-23.
25. Budiharto T., Joniau S., Lerut E., et al. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. Eur Urol 2011, 60:125-130.
26. Saokar A., Islam T., Jantsch M., et al. Detection of lymph nodes in pelvic malignancies with computed tomography and magnetic resonance imaging. Clin Imaging 2010, 34:361-366.
27. Mir N., Sohaib S.A., Collins D., et al. Fusion of high b-value diffusion-weighted and T2 weighted MR images improves identification of lymph nodes in the pelvis. J Med Imaging Radiat Oncol 2010, 54:358-364.
28. Evangelista L., Guttilla A., Zattoni F., et al. Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol 2012, [Epub ahead of print]. 10.1016/j.eururo.2012.09.039.
29. Giovacchini G., Picchio M., Coradeschi E., et al. Predictive factors of [(11)C]choline in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010, 37:301-319.
30. Krause B.J., Souvatzoglou M., Tuncel M., et al. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008, 35((1) January):18-23.
31. Vees H., Buchegger F., Albrecht S., et al. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1ng/mL) after radical prostatectomy. BJU Int 2007, 99((6) June):1415-1420.
32. 11C-choline PET-CT in prostate cancer patients with biochemical relapse. Theranostics 2012, 2(3):313-317.
33. Kim B.S., Lashkari A., Vongtama R., et al. Effect of pelvic lymph node irradiation in salvage therapy for patients with prostate cancer with a biochemical relapse following radical prostatectomy. Clin Prostate Cancer 2004, 3:93-97.
34. NCCN Prostate Cancer guidelines at. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
35. Smith M.R., Finkelstein J.S., McGovern F.J., et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002, 87((2) February):599-603.
36. Braga-Basaria M., Dobs A.S., Muller D.C., et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. Clin Oncol 2006, 24((24) August):3979-3983.
37. Basaria S., Muller D.C., Carducci M.A., et al. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006, 106(3):581-588.
38. Smith M.R., Lee H., Nathan D.M. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006, 91((4) April):1305-1308.
39. Keating N.L., O'Malley N.L., Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006, 24((27) September):4448-4456.
40. Cheng L., Zincke H., Blute M.L., et al. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 2001, 91:66-73.
41. Gjertson C.K., Asher K.P., Sclar J.D., et al. Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era. Urology 2007, 70:723-727.
42. Schumacher M.C., Burkhard F.C., Thalmann G.N., et al. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 2008, 54:344-352.
43. Schmidt J.D. The patient, disease status, and treatment options for prostate cancer: stages D1 and D2. Prostate 1983, 4(5):493-501.
44. Cheng W.S., Bergstralh E.J., Frydenberg M., Zincke H. Prostate-specific antigen levels after radical prostatectomy and immediate adjuvant hormonal treatment for stage D1 prostate cancer are predictive of early disease outcome. Eur Urol 1994, 25(3):189-193.
45. Ryan C.J., Small E.J. Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate. J Clin Oncol 2005, 23:8225-8231.
46. Briganti A., Karnes R.J., Da Pozzo L.F., et al. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol 2011, 59((5) May):832-840.
47. Messing E.M., Manola J., Yao J., et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006, 7((6) June):472-479.
48. Wong Y.N., Freedland S., Egleston B., et al. Role of androgen deprivation therapy for node-positive prostate cancer. J Clin Oncol 2009, 27((1) January):100-105.
49. Lawton C.A., Winter K., Grignon D., Pilepich M.V. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol 2005, 23((4) February):800-807.
50. Sgrignoli A.R., Walsh P.C., Steinberg G.D., et al. Prognostic factors in men with stage D1 prostate cancer identification of patients less likely to have prolonged survival after radical prostatectomy. J Urol 1994, 152:1077-1081.
51. Daneshmand S., Quek M.L., Stein J.P., et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 2004, 172:2252-2255.
52. Hofer M.D., Kuefer R., Huang W., et al. Prognostic factors in lymph node-positive prostate cancer. Urology 2006, 67((5) May):1016-1021.
53. Roach M., Lu J., Pilepich M.V.
54. Rinnab L., Mottaghy F.M., Simon J., et al. [11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study. Urol Int 2008, 81:191-197.
55. Winter A., Uphoff J., Henke R.P., Wawroschek F. First results of [11C]choline PET/CT-guided secondary lymph node surgery in patients with PSA failure and single lymph node recurrence after radical retropubic prostatectomy. Urol Int 2010, 84:418-423.
56. Martini T., Mayr R., Trenti E., et al. The role of C-choline-PET/CT-guided secondary lymphadenectomy in patients with PSA failure after radical prostatectomy: lessons learned from eight cases. Adv Urol 2012, 2012:601572.
57. Schilling D., Schlemmer H.P., Wagner P.H., et al. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int 2008, 102:446-451.
58. Rigatti P., Suardi N., Briganti A., et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. Eur Urol 2011, 60((5) November):935-943.
59. Picchio M., Briganti A., Fanti S., et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol 2011, 59:51-60.
60. Suardi N., Briganti A., Salonia A., Rigatti P. Salvage lymphadenectomy in postprostatectomy patients with prostate-specific antigen recurrence. Curr Opin Urol 2011, 21((3) May):237-240.
61. Tilki D., Reich O., Graser A., et al. 18F-fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent. Eur Urol 2012, [Epub ahead of print]. 10.1016/j.eururo.2012.08.003.
62. Yim J.H., Kim W.B., Kim E.Y., et al. The outcomes of fi{ligature}rst reoperation for locoregionally recurrent/persistent papillary thyroid carcinoma in patients who initially underwent total thyroidectomy and remnant ablation. J Clin Endocrinol Metab 2011, 96:2049-2056.
63. Keating N.L., O'Malley A.J., Freedland S.J., Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010, 102:39-46.
64. Jilg C.A., Rischke H.C., Reske S.N., et al. Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol 2012, 188((6) December):2190-2197.
65. Heidenreich A., Bellmunt J., Bolla M., et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011, 59:61-71.
66. Jereczek-Fossa B.A., Orecchia R. Evidence-based radiation oncology: definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer. Radiother Oncol 2007, 84:197-215.
67. Alongi F., De Bari B., Franco P., et al. The PROCAINA (PROstate CAncer INdication Attitudes) Project (Part I) - a survey among Italian radiation oncologists on post-operative radiotherapy in prostate cancer. Radiol Med 2013, 118((4) June):660-678.
68. De Bari B., Alongi F., Franco P., et al. The PROCAINA (PROstate CAncer INdication Attitudes) Project (Part II) - a survey among Italian radiation oncologists on radical radiotherapy in prostate cancer. Radiol Med 2013, 118((7) October):1220-1239.
69. Magrini S.M., Bertoni F., Vavassori V., et al. Practice patterns for prostate cancer in nine central and northern Italy radiation oncology centers: a survey including 1759 patients treated during two decades (1980-1998). Int J Radiat Oncol Biol Phys 2002, 52((5) April):1310-1319.
70. Alongi F., Fiorino C., Cozzarini C., et al. IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol 2009, 93:207-212.
71. Cozzarini C., Di Muzio N. Contemporary role of radiation therapy in the adjuvant or salvage setting following radical prostatectomy. Curr Opin Urol 2011, 21:206-210.
72. Alongi F., Schipani S., Gajate A.M., et al. [11C]choline-PET-guided helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate cancer: local control and toxicity profile after 24 months. Tumori 2010, 96:613-617.
73. Chapet O., Quero L., Azria D., et al. Is pelvic irradiation still justified in the treatment of prostate cancer by exclusive radiotherapy?. Cancer Radiother 2009, 13((5) September):416-422.
74. Ricchetti F., Barra S., Agostinelli S., et al. Feasibility of helical tomotherapy for radical dose retreatment in pelvic area: a report of 4 cases. Tumori 2011, 97:492-497.
75. Engels B., Soete G., Tournel K., et al. Helical tomotherapy with simultaneous integrated boost for high-risk and lymph node-positive prostate cancer: early report on acute and late toxicity. Technol Cancer Res Treat 2009, 8:353-359.
76. Alongi F., Schipani S., Gajate A.M., et al. [11C]choline-PET-guided helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate cancer: local control and toxicity profile after 24 months. Tumori 2010, 96((4) July-August):613-617.
77. Kupelian P., Langen K. Helical tomotherapy: image-guided and adaptive radiotherapy. Front Radiat Ther Oncol 2011, 43:165-180.
78. Alongi F., Arcangeli S., Filippi A.R., et al. Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist 2012, 17(8):1100-1107.
79. Scorsetti M., Bignardi M., Alongi F., et al. Stereotactic body radiation therapy for abdominal targets using volumetric intensity modulated arc therapy with RapidArc: feasibility and clinical preliminary results. Acta Oncol 2011, 50:528-538.
80. Thariat J., Li G., Angellier G., et al. Current indications and ongoing clinical trials with CyberKnife stereotactic radiotherapy in France in 2009. Bull Cancer 2009, 96:853-864.
81. Leborgne F., Fowler J., Leborgne J.H., Mezzera J. Later outcomes and alpha/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82:1200-1207.
82. Arcangeli S., Scorsetti M., Alongi F. Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review. Crit Rev Oncol Hematol 2012, [Epub ahead of print].
83. Jereczek-Fossa B.A., Piperno G., Ronchi S., et al. Linac-based stereotactic body radiotherapy for oligometastatic patients with single abdominal lymph node recurrent cancer. Am J Clin Oncol 2012, [Epub ahead of print].
84. Jereczek-Fossa B.A., Beltramo G., Fariselli L., et al. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastastic prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82:889-897.
85. Jereczek-Fossa B.A., Fariselli L., Beltramo G., et al. Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer. Radiother Oncol 2009, 93:14-17.
86. Katz E.E., Harding J.N., Brendler C. Return of serum prostate specific antigen to undetectable level following removal of solitary lymph node metastasis. J Urol 2002, 168:2546.
87. Kondziolka D., Niranjan A., Kano H., et al. knife radiosurgery of other brain metastases. Prog Neurol Surg 2012, 25:190-200.
88. Pruthi R.S., Hubbard J.S., Kouba E., Wallen E. Androgen-independent prostate cancer treated with resection of the solitary metastatic site. Urol Int 2007, 9:371-373.
89. Sakamoto N., Eto M., Ando S. Surgical excision of a metastatic adrenal lesion in a patient with prostatic cancer. Int J Urol 1999, 6:38-40.
90. Bignardi M., Cozzi L., Fogliata A., et al. Critical appraisal of volumetric modulated arc therapy in stereotactic body radiation therapy for metastases to abdominal lymph nodes. Int J Radiat Oncol Biol Phys 2009, 75:1570-1577.
91. Milano M.T., Constine L.S., Okunieff P. Normal tissue toxicity after small field hypofractionated stereotactic body radiation. Radiat Oncol 2008, 3:36. (review).